The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be influenced by individual clinical features or by patterns of risk factors and comorbidities. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. non-vitamin K oral anticoagulants (NOACs) for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In addition, we discuss the timing of initiation of anticoagulation. In the second of a two-part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or transient ischaemic attack (TIA), (viii) patients with acute stroke requiring thrombolysis or thrombectomy, (ix) those initiating or restarting OAC treatment after stroke or TIA, (x) those with renal impairment on dialysis, (xi) the elderly, (xii) those at high risk of gastrointestinal bleeding, and (xiii) those with hypertension. In addition, we discuss adherence and compliance. Finally, we present a summary of treatment suggestions. In specific subgroups of patients with AF, evidence supports the use of particular NOACs and/or particular doses of anticoagulant. The appropriate choice of treatment for these subgroups will help to promote optimal clinical outcomes.
Introduction
This review, like part 1, is based on sub-analyses of the major trials of non-vitamin K oral anticoagulants (NOACs). 1 -4 In the absence of data from the main trials, our suggestions are based on expert opinion only.
On the basis of our review of the data, we offer suggestions-reflecting a consensus of the authors-for choice of NOAC and/or dose in subgroups of patients with atrial fibrillation (AF) and the timing of initiation of anticoagulation after stroke or intracranial bleeding. There is a clear need to evaluate some of the proposed management strategies in prospective, randomized trials. At the time of writing of this report, there is insufficient evidence to support firm recommendations. This report is thus meant to support clinical decision making when used in conjunction with treatment guidelines 5 
and the European Heart
Rhythm Association guide on practical aspects of NOAC therapy. 6 We added a section on adherence and reversal agents. In the future, when more data are available these issues might have an impact on the choice of OAC and treatment decisions may change.
Secondary stroke prevention
Warfarin is superior to aspirin and placebo in prevention of recurrent stroke after transient ischaemic attack (TIA) or stroke in patients with AF. 7 All randomized trials comparing NOACs with warfarin had subgroups of patients with prior stroke or TIA. 8 -10 Detailed data for edoxaban have not been published. 4 The AVERROES trial, which compared apixaban with aspirin in patients with AF, also had a secondary stroke prevention subgroup. 11 The stroke-TIA subgroups were too small to allow statistical comparisons of the NOACs with warfarin, but tests of heterogeneity found no differences in safety or efficacy among patients with and without prior stroke or TIA. In a meta-analysis of 14 527 patients with prior stroke or TIA from RE-LY, ARISTOTLE, and ROCKET AF, NOACs were associated with a significant reduction in the incidence of stroke and systemic embolism compared with warfarin [odds ratio (OR) 0.85; 95% confidence interval (CI) 0.74-0.99]. 12 The NOACs were also associated with less major bleeding than warfarin (OR 0.86; 95% CI 0.75-0.99), mainly due to a reduction in the incidence of haemorrhagic stroke (OR 0.44; 95% CI 0.32-0.62). 12 It should be noted, however, that the time in therapeutic range for the warfarin-treated patients in these trials was on average ,70%. For secondary stroke prevention, apixaban superior efficacy compared with aspirin [hazard ratio (HR) 0.29; 95% CI 0.15-0.60], with a comparable risk of bleeding.
11
After TIA or stroke, combination therapy with an OAC and antiplatelet agent is not advisable. Compared with an OAC alone, combination therapy did not prevent ischaemic endpoints, but increased the risk of major bleeding. 13 For patients suffering ischaemic stroke or TIA during well-titrated warfarin therapy, substitution with an NOAC is reasonable. Based on our interpretation of available data we suggest:
First choice NOACs as a group are superior to warfarin for secondary stroke prevention in patients with AF Comment Aspirin should not be used for secondary stroke prevention in patients with AF. The combination of antiplatelet therapy plus OAC in patients with AF does not prevent major ischaemic events better than does OAC monotherapy and should be restricted to specific high-risk periods
Patients with acute stroke requiring thrombolysis or thrombectomy Anticoagulants, including NOACs, present special challenges for the emergency management of ischaemic stroke. Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) within 4.5 h after symptom onset is currently the only licensed medical therapy for stroke. As per licence, anticoagulation is a contraindication to thrombolysis because it can increase the risk of intracerebral haemorrhage. In a recent series, almost 10% of acute ischaemic stroke patients were taking vitamin K antagonists (VKAs) at the time of the event. 14 However, up to 20% of patients with acute stroke are unable to convey information about anticoagulation status when presenting in the emergency room. Rapid assessment of coagulation status at presentation is necessary to guide a decision for or against thrombolysis. For those taking a VKA, this can be done quickly by using a point-of-care device to measure the international normalized ratio (INR). 15 Beyond the qualitative determination of whether a patient is anticoagulated, the threshold intensity at which thrombolysis can safely be used is uncertain. 16 Data from two large observational registries in the USA and Europe suggest that thrombolysis does not increase the risk of intracerebral haemorrhagic complications in patients on VKA when the INR is ≤1.7.
17,18
In randomized trials of anticoagulation, the annual risk of ischaemic stroke among patients with AF ranged from 1 -2% for primary to 2 -3% for secondary stroke prevention. 19 Experience with patients taking VKA suggests that low levels or an absence of anticoagulation with NOACs might allow thrombolysis with rtPA. Extrapolation of intracerebral haemorrhagic risk may not be appropriate, and safety thresholds for the NOACs have not been established. An observational study in 78 patients on NOACs undergoing systemic thrombolysis and or thrombectomy showed no increased bleeding risk. 20 During long-term therapy, the risk of spontaneous intracerebral haemorrhage in patients treated with NOACs was consistently about half that during VKA therapy, and pharmacodynamic differences may contribute to this difference in rates of intracranial haemorrhage (ICH). 19 In preclinical experiments, haemorrhagic transformation of brain infarcts after thrombolysis is elevated in rodents exposed to VKA but not in those given NOACs when compared with animals that were not anticoagulated. 21, 22 Management of ischaemic stroke in patients treated with NOACs must balance efficacy against safety concerns. Timing of treatment according to the 1-3-6-12 day rule
In patients with AF and TIA, OAC including NOACAs treatment may be initiated on the first day after neuroimaging has excluded ICH. The 1 -3 -6 -12 day rule is not based on evidence and has not been derived from controlled trials In patients with mild ischaemic stroke, OAC treatment may be initiated after 3 days. In patients with strokes of moderate severity, anticoagulation may be started after 5-7 days. In patients with severe strokes, anticoagulation may be initiated after 12-14 days. Comment Brain imaging should be repeated before anticoagulation in patients with moderate or severe stroke to exclude haemorrhagic transformation
Patients with a high risk of gastrointestinal bleeding
Several of the NOACs increase the risk of major gastrointestinal bleeding (MGIB) relative to adjusted-dose warfarin in patients with AF. In RE-LY, dabigatran 150 mg twice daily was associated with a higher rate of MGIB compared with warfarin [relative risk (RR) 1.50], but the MGIB risk with dabigatran 110 mg twice daily was comparable with that of warfarin (RR 1.10). 1 An increased RR of MGIB with dabigatran was seen only in patients aged ≥75 years 26 and with respect to lower but not upper gastrointestinal bleeding.
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Most post-market studies confirm the RRs of MGIB seen in RE-LY. A propensity-matched analysis from the US Center for Medicare and Medicaid Services (CMS) database showed an increased risk of MGIB in patients receiving dabigatran (pooled data from 150 to 75 mg twice daily doses) compared with warfarin (HR 1.28). 27 The increased risk in dabigatran users involved women aged ≥75 years and men aged ≥85 years. The MGIB rate in patients taking dabigatran 75 mg twice daily was comparable with that of warfarin (HR 1.01). A US Veteran's Affairs database study (pooled dabigatran doses) showed an increased rate of MGIB among warfarin users who switched to dabigatran compared with those who remained on warfarin. 28 A smaller non-FDA CMS database study confirmed an increased rate of MGIB with dabigatran (pooled doses) compared with warfarin. 29 Two population-based cohort studies in US subjects suggest that the increased MGIB risk for dabigatran vs. warfarin involves mainly patients aged .75 years. 30, 31 However, two observational studies from Denmark failed to confirm excess MGIB with dabigatran compared with warfarin. 32, 33 A community-based study suggested that dabigatran-related gastrointestinal bleeding was associated with clinical outcomes comparable with those of warfarin-related bleeding. 34 A study from Hong Kong in 5041 patients newly prescribed dabigatran showed a reduced risk of gastrointestinal bleeding in patients taking gastroprotective agents. 35 In ROCKET AF, patients receiving rivaroxaban 20 mg once daily had a significantly higher risk of MGIB than did those on warfarin (3.2 vs. 2.2%; P , 0.001), 3 but the incidence of both life-threatening and fatal gastrointestinal bleeds was similar in the two arms. 36 In ROCK-ET AF, a greater MGIB risk was noted with rivaroxaban compared with warfarin in patients aged ≥75 years. 37 This interaction between age and MGIB risk was confirmed in a population-based cohort study. 30 Rivaroxaban has been associated with upper gastrointestinal bleeding more frequently than lower gastrointestinal bleeding. 38 However, two studies failed to confirm a significant difference in RR of MGIB between rivaroxaban and warfarin. 39, 40 The ARISTOTLE trial showed a comparable rate of MGIB in the apixaban 5 mg twice daily and the warfarin arms (HR 0.89). 2 The ENGAGE AF study showed an increased risk with high-dose edoxaban (60 mg daily) vs. With the dose reductions (based at least in part on renal function) that were part of the protocols in three of the four warfarincomparator trials, the results were consistent for patients with creatinine clearance of 30 -49 mL/min. 46 -48 These findings provide confidence that NOACs can be safe and effective, compared with warfarin, for patients with moderate renal impairment. The AVER-ROES trial found that the benefit of apixaban compared with aspirin was similar in patients with and without Stage III CKD. 45 In the AR-ISTOTLE trial, the major bleeding rate in patients with moderate renal impairment was lower with apixaban than with warfarin. 48 In contrast, major bleeding was similar with dabigatran (both doses) and warfarin in the RE-LY trial 47 and with rivaroxaban 20 mg daily and warfarin. 46 There are no clinical outcome data regarding the use of NOACs for patients with creatinine clearance (calculated by the CockroftGault equation) of ,30 mL/min. This includes patients on haemodialysis, 49 for whom warfarin provides uncertain benefit. 50 Until trial outcome data are available, warfarin is the preferred anticoagulant for these patient subgroups. 49 The FDA has approved apixaban for patients on haemodialysis without safety data from this population. The FDA review of the ENGAGE AF trial raised a question of efficacy among patients with high normal creatinine clearance (.95 mL/min), and resulting lower plasma concentration of drug: http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisory Committee/UCM421613.pdf). There was a statistically lower treatment effect (interaction P ¼ 0.002) for prevention of ischaemic stroke with edoxaban compared with warfarin for patients with creatinine clearance .95 mL/min, and a higher stroke rate with edoxaban in this subgroup. Whether this was due to under-dosing of edoxaban, particular effectiveness of warfarin in this subgroup, or a combination of factors is not known.
Based on our interpretation of available data we suggest: 
Non-vitamin K oral anticoagulants and age
The risks of both bleeding and stroke increase with age. Older age is the reason often given for not prescribing anticoagulants for individuals aged over 80 years. 51 Given the high risk for ischaemic stroke, anticoagulant therapy offers net clinical benefit for older adults, including those at risk of falls. 54 Compared with VKAs, all of the NOACs reduced the incidence of ICH. All of the AF trials confirmed the increased risk of major bleeding among older adults compared with younger individuals ( Table 2 ). In the RE-LY trial, there was a significant treatment-by-age interaction for major bleeding. 26 Compared with warfarin, the 110 mg twice daily dabigatran dose was associated with a lower risk of major bleeding among patients ,75 years old and similar risk among those ≥75 years. The higher dose of dabigatran, 150 mg twice daily, was associated with a lower risk of bleeding in the younger group, but trended to higher risk among those patients ≥75 years. Both doses reduced ICH compared with warfarin, regardless of patient age. In the ARISTOTLE trial, the rate of major bleeding with apixaban 5 mg twice daily compared with warfarin was lower for the older age groups (65 -74, ≥75 years; Table 2 ). The dose of apixaban, 5 mg twice daily, was reduced to 2.5 mg twice daily in patients with two of the following characteristics: age ≥80 years, weight ≤60 kg, and creatinine ≥1.5 mg/dL (133 mmol). 55 There was no treatment-by-age interaction for major bleeding among participants enrolled in the ROCKET AF trial, which found similar rates of bleeding with rivaroxaban and warfarin in each age stratum. A reduced dose of rivaroxaban, 15 mg per day, was used in those with reduced renal function (30-49 mL/min). In the ENGAGE AF trial, edoxaban 60 mg daily was associated with a lower risk of major bleeding among patients aged ,75 years compared with warfarin, and similar rates among those ≥75 years of age. The edoxaban dose was reduced by half in patients with reduced renal function (30 -50 mL/min), with weight ≤60 kg, or with concomitant use of verapamil, quinidine, or dronedarone. Based on our interpretation of available data we suggest: The trials were different in the baseline risk for bleeding complications.
Patients with hypertension
Hypertension is a powerful risk factor for stroke in patients with and without AF, and a risk factor for bleeding in anticoagulated patients. The NOACs have been extensively evaluated for stroke prevention in patients with AF who are eligible for OAC treatment with VKAs in the presence or absence of hypertension (Tables 3 and 4) . There are no specific data on the risk of bleeding in patients with or without hypertension during therapy with dabigatran or rivaroxaban. Results for apixaban and edoxaban are shown in Table 4 . In patients with hypertension, HRs vary from 0.69 to 0.80 for safety and 0.64 to 0.84 for efficacy compared with warfarin, but confidence intervals are wide and overlapping, and the inherent limitations of cross-trial comparisons preclude preferential recommendations for one anticoagulant agent over another. Based on our interpretation of available data we suggest:
Choice of NOAC
No particular NOAC is superior to another NOAC in terms of safety or efficacy in patients with AF and hypertension
Adherence
Non-adherence to chronic OAC treatment increases the risks of both ischaemic and haemorrhagic complications. 57, 58 Enthusiasm for the convenience of fixed-dose NOACs has been paralleled by concerns about patient adherence given the shorter half-lives of these agents compared with VKAs, and inability to reliably and readily measure the anticoagulant effect of NOACs. 59 No published data are available from the phase III trials regarding adherence to NOACs, other than overall discontinuation rates. There are limited data from experience in clinical practice, with five studies reporting adherence and/or persistence rates for dabigatran, 60 -64 and two reporting persistence data for rivaroxaban. 40, 65 Those reporting dabigatran adherence data used 80% or more as the threshold for good adherence, determined by the proportion of days covered (number of days in which the medication was taken as prescribed). 60 -62 One small study (n ¼ 99) reported 88% adherence to dabigatran over a variable follow-up period, 64 while larger studies report median adherence rates of 67 -77%. 40 but methodological, demographic, and clinical differences between these studies including length of follow-up may account for the differences in reported rates of adherence and persistence with therapy.
Reducing the complexity of a medication regimen or frequency of dosing does not necessarily improve adherence, 66 although the proportion of doses taken is generally greater with once-daily vs. twice-daily dosing. 67 -69 There are no significant differences in persistence rates between dosing regimens. 68 Drug-action depends on both the frequency and timing of dosing, and there is insufficient evidence to advocate once or twice daily dosing to improve adherence to NOAC therapy. To date, no interventions have been shown to improve adherence to NOAC therapy. The impact of adherence to apixaban is under investigation in the Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation study (NCT0188435), in which 'usual care' is compared with 'usual care plus education supported by a virtual clinic', with adherence recorded using an electronic device that gathers data based on the timing of removal of medication from the device.
Patient engagement in treatment decisions, and education about AF, stroke, and drug-specific information ( Table 5 ) are essential to improve adherence. The mode of delivery and complexity of information should be adapted to the individual patient. 70, 71 The importance of sustained adherence must be communicated so patients are aware of the potential consequences of non-adherence. Adherence should be measured. Identifying the patterns of and reasons for nonadherence are valuable in developing individualized strategies to improve adherence and outcomes.
69 Based on our interpretation of available data we suggest:
Choice of OAC OACs should not be used in patients where intentional non-adherence is known (i.e. choosing not to take medication) When medication, non-adherence is unintentional (due to cognitive impairment or other impediments), strategies such as pill-boxes or engagement of a family member or caregiver to oversee administration of OAC medication should be used. NOACs may be more appropriate than VKA agents in this situation, given their fixed dose and simpler regimen The decision of which NOAC to prescribe should not be based primarily on once vs. twice daily dosing, but this may be a factor in the decision-making process for some patients (i.e. polypharmacy, patient preference) There is no evidence to support the use of a particular NOAC
Limitations and caveats
The suggestions presented in this two-part expert consensus paper ( Figure 1 ) were developed by experienced clinicians and investigators based on present and evolving data. Some suggestions have been made in the absence of data by consensus or majority decision of the group of authors. Although we comprehensively reviewed and summarized the literature, our search was not systematic or exhaustive and new data are emerging rapidly. Readers should remain alert to evolving evidence. We have not graded the quality of evidence objectively or systematically, and the strength of suggestions is variable and in some cases limited. Readers should also be aware that this consensus statement was developed by individuals who were engaged in the development and clinical evaluation of the NOACs in clinical trials, and that data collected from broad clinical practice are still limited. Finally, in developing advice for the management of patients with specific comorbidities, it is not possible to capture the unique characteristics of individuals and their concomitant therapy, which require case-by-case assessment by physicians and other prescribers, with comprehensive knowledge of the patient's likelihood of tolerating one therapy over another and the patient's expressed values and preferences. 
